Remedium Bio
PrivateLast Round
Series A
Aug 10, 2026
Total Funding Raised
$20.72M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Remedium Bio is a biotechnology company that develops gene therapies for large unmet clinical needs using its proprietary Prometheus™ adjustable gene therapy platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Remedium Bio Comparables
Compare Remedium Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Addition Therapeutics | 84% | |
| Canary Cure Therapeutics | 79% | |
| Genprex, Inc. | 77% |
Remedium Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 10, 2026 | ||||
| Seed Round | May 18, 2026 | ||||
| Series A | Sep 8, 2025 | ||||
| Grant | Sep 30, 2024 | ||||
| Grant | Sep 1, 2024 | ||||
Grant | Nov 24, 2023 |
Remedium Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Apis Health Angels | Seed |
| Wharton Alumni Angels | Grant |
| Longevitytech.fund | Seed |
| VitaDAO | Grant |
| HKX Capital | Series A |
| Bill & Melinda Gates Foundation | Grant |
| The Bill & Melinda Gates Foundation Trust | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 44% MoM.
- Aug 17, 2026
Grew 25% QoQ, from 16 to 20 employees.
Recent news
Latest coverage and updates
- is_developingAug 10, 2026
Remedium Bio, Inc. is developing adjustable gene therapies for chronic disease.
- is_developingAug 10, 2026
Remedium Bio, Inc. is developing durable protein therapeutics on Aug 10th '26.
- receives_financingAug 10, 2026
Remedium Bio, Inc. received financing of $10M in Series A on Aug 10th '26.
- hiresAug 10, 2026
Remedium Bio, Inc. hired Harry Robb as Board of Directors on Aug 10th '26.
Remedium Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Remedium Bio's valuation, stock price, and market status.
Is Remedium Bio a public or private company?
Remedium Bio is a private company.
What is the current stock price of Remedium Bio?
Remedium Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Remedium Bio worth (valuation)?
Valuation information for Remedium Bio is not publicly available.
Can I buy Remedium Bio stock?
Remedium Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Remedium Bio's last funding round?
Remedium Bio's most recent funding round was Seed Round on May 18, 2026.
Who are the main investors in Remedium Bio?
Key investors in Remedium Bio include Sherwood Ventures.
Will Remedium Bio IPO soon?
No public IPO plans have been announced for Remedium Bio.
How can I track Remedium Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Remedium Bio's secondary market activity and sign up for updates.